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Abstract 
PURPOSE: Pre-menopausal women with cancer are at risk of therapy-associated infertility, 
premature menopause, and sexual dysfunction. However, it is unknown whether oncologists 
adequately address these risks during treatment planning. We conducted a study to evaluate 
physician-patient discussions addressing the impact of cancer treatment and actual treatment 
effects on fertility, menopause status, and general sexual health. 
METHODS: A questionnaire was administered in four oncology clinics specializing in breast, 
gynecologic, general hematology-oncology, and blood and marrow transplantation (BMT) 
cancer care at a single institution. Eligible participants were pre-menopausal at the time of 
diagnosis and either actively receiving or within 24 months from completion of treatment. 
Participants completed the questionnaire at enrollment and at 1-year follow-up.  
RESULTS: Of the 104 eligible women, a majority were satisfied with the quality (68%) and 
length (66%) of reproductive health discussions, with the highest satisfaction levels in the 
gynecologic cancer clinic (85%) and the lowest levels  in the BMT clinic (53%). Fertility 
preservation was desired by 20% of women, including some >40 years old. Women were 
more interested in discussing treatment impact on menopause status and sexual health than 
fertility. Rates of discussions on treatment impact on sexual health were low despite 77% of 
women reporting severe sexual dysfunction at 1-year follow-up.  
CONCLUSIONS: One-third of women are dissatisfied with the quality and length of discus-
sions regarding the impact of cancer treatment on reproductive health. There is notably 
inadequate counseling on the effect of treatment on fertility in women > 40 and on sexual 
function in all women. Oncologists must offer better resources and improve communication 
on the effect of treatment on reproductive health to pre-menopausal women with cancer. 
Key words: Cancer, Fertility, Physician-Patient Discussions, Women, Sexual Health. 
Introduction 
As the population of cancer survivors continues 
to  grow,  it  is  becoming  increasingly  imperative  for 
oncologists to identify and address important quali-
ty-of-life issues that negatively affect the well-being of 
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their  patients.  Over  60%  of  cancer  survivors  in  the 
United States are women.1 Quality-of-life concerns for 
these cancer survivors create new challenges for on-
cologists  to  address  during  treatment  planning  and 
long-term follow-up. Recent studies show that young 
women with cancer have concerns related to sexual 
health,  treatment-induced  infertility,  and  meno-
pause.2-4 While the importance of these quality-of-life 
issues is ill-defined, it is clear that these common side 
effects of cancer treatment occur.  
Chemotherapy may reduce the number of viable 
ovarian  follicles  in  a  drug  and  dose-dependent  re-
sponse, and surgical or radiation treatment may in-
duce changes in uterine, fallopian, or ovarian anato-
my which interferes with a woman’s ability to con-
ceive  after  cancer  therapy  is  completed.5  Young 
women  experiencing  chemotherapy  or  surgical-
ly-induced  amenorrhea  are  likely  to  exhibit  meno-
pausal  symptoms,  including  hot  flashes,  insomnia, 
and  fatigue.6  Chemotherapy,  surgery,  radiation,  or 
endocrine  treatment  may  also  result  in  sexual  dys-
function,  such  as  loss  of  libido,  vaginal  dryness, 
dyspareunia,  and  decreased  personal  and  partner 
satisfaction.7,8 Sexual dysfunction affects up to 90% of 
women treated for breast cancer, with vaginal dryness 
being  the  most  significant  indicator  of  long-term 
problems in sexual functioning. 7-12 Many other factors 
may contribute to chronic sexual dysfunction includ-
ing the psychological effects of the cancer diagnosis, 
anxiety of recurrence, depression, and impaired body 
image. Physician-patient counseling about the impact 
of  cancer  treatment  on  general  reproductive  health 
should be an integral part of the patient care experi-
ence for pre-menopausal women with cancer. 
Recent surveys of cancer survivors of reproduc-
tive age show that a majority have no recollection of 
discussing fertility at the time of treatment planning.13 
The American Society of Clinical  Oncology (ASCO) 
has recognized the need for improvement in physi-
cian-patient  counseling  on  these  topics.  ASCO  has 
created specific recommendations to guide physicians 
in discussing with patients the possibility of infertility 
due  to  cancer  therapy  and  offering  referrals  to  re-
productive specialist care. Over half of physicians are 
not following these recommendations for reproduc-
tive-age patients in terms of offering fertility specialist 
care to those patients who are interested in preserving 
fertility and at risk for treatment-induced infertility.13 
Few data exists on the personal importance of such 
discussions on fertility and sexual health for women 
facing  a  new  cancer  diagnosis.  The  purpose  of  the 
present  study  was  to  determine  whether  fertility, 
menopause status, and sexual health were important 
quality-of-life  concerns  among  pre-menopausal 
women  with  cancer  and  whether  oncologists  dis-
cussed  these  concerns  adequately  during  treatment 
planning and long-term follow-up. 
Methods 
Patients  
All subjects were recruited from the University 
of  Minnesota  Cancer  Clinics  by  study  investigator, 
M.S., who had no direct involvement in their clinical 
care.  The  subjects  were  either  receiving  care  in  the 
general hematology-oncology clinic or in one of three 
sub-specialty  clinics  focused  on  breast,  gynecologic, 
or  blood  and  marrow  transplantation  (BMT)  cancer 
care. These four clinics were staffed with designated 
and  non-overlapping  oncologists.  Informed  consent 
was obtained by investigator M.S. in the clinic prior to 
screening patients for eligibility. Women were eligible 
to participate in this study if they had a histologically 
proven diagnosis of cancer, were 18 years of age or 
older, and were actively receiving cancer therapy or 
within 24 months from the end of their cancer treat-
ment. All subjects were pre- or peri-menopausal at the 
time  of  their  cancer  diagnosis,  as  defined  by  the 
presence of at least two menstrual periods within 6 
months of diagnosis. Subjects were excluded if they 
were post-menopausal at diagnosis or had metastatic 
disease.  
Study design 
We conducted a longitudinal cohort study of all 
eligible female cancer patients receiving treatment at 
our institution. Participants were asked to complete 
an original 24-item questionnaire (see Supplementary 
Material)  designed  to  assess  discussions  they  had 
with their treating oncologist. We evaluated patient 
satisfaction levels of the physician-patient discussions 
regarding  treatment  impact  on  fertility,  menopause 
status, and sexual health, as well as the personal im-
portance of having such discussions on these topics. 
The questionnaire was divided into three sections to 
assess these discussions throughout the spectrum of 
cancer care, to include: before cancer diagnosis, dur-
ing treatment planning, and at the time of study en-
rollment.  A  follow-up  survey  on  these  topics  was 
administered by mail one year after enrollment and it 
was comprised of repeated sections from the original 
questionnaire  concerning  the  overall  discussion  sat-
isfaction  ratings  and  treatment  impact  on  sexual 
health. A second mailing with the follow-up survey 
was sent to those patients who did not respond to the 
original request. Questionnaire data was linked with 
information  extracted  from  the  medical  record,  in-
cluding date of birth, age at diagnosis, menopausal  Journal of Cancer 2012, 3 
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status at the time of diagnosis, tumor histology, stage 
at diagnosis, and all cancer treatment received. The 
protocol and analysis were approved by the Univer-
sity of Minnesota Institutional Review Board. All pa-
tients provided written informed consent according to 
the Declaration of Helsinki.  
Statistics 
Each questionnaire item was summarized by the 
number and percent for each response. The percent-
ages were based on the number of women who an-
swered  the  question,  unless  that  question  was  not 
applicable (N/A), in which case the subject was not 
counted. Items on the Likert scale of 1 (very negative) 
to 5 (very positive) were reduced into three categories 
(1+2,  3,  4+5)  for  reporting  purposes.  However,  for 
comparisons between patient groups - such as disease 
type, age groups and gender of oncologist - the orig-
inal 5-level ordinal scale was analyzed by either the 
non-parametric Kruskal-Wallis test or Wilcoxon rank 
sum test. Other questionnaire items were evaluated 
between groups using Fisher’s exact test. Infrequent 
responses such as “Unsure” or “Cannot recall” were 
excluded  from  statistical  comparisons  to  improve 
interpretation  of  results.  Changes  in  women’s  re-
sponses  between  the  initial  questionnaire  and  the 
same questions asked on the follow-up questionnaire 
were  evaluated  by  McNemar’s  chi-square  test.  For 
these  before-and-after  comparisons,  just  two  Likert 
subcategories (1+2+3 and 4+5) were used. All statis-
tical analyses were performed using SAS version 9.2 
(SAS Institute Inc., USA). A p-value of <0.05 was con-
sidered statistically significant.  
Results 
Patient characteristics 
One  hundred  and  twenty-six  women  were 
screened,  with  114  consenting  to  participate.  Ten 
women  were  excluded  upon  final  eligibility  review 
due  to  the  lack  of  malignancy  (n=4)  and 
post-menopausal  status  at  cancer  diagnosis  (n=6), 
resulting in 104 evaluable subjects divided into four 
disease-specific cohorts (Table 1). Enrollment  in the 
study  occurred  at  a  median  time  of  2.4  years  after 
cancer  diagnosis.  Gender  of  the  treating  oncologist 
was approximately evenly distributed between males 
(47%)  and  females  (52%).  Median  age  at  study  en-
rollment was 40.5 years (range, 18-52 years). Most of 
the participants were either married or single and in a 
relationship (77%). Sixty-seven (64%) women experi-
enced treatment-induced amenorrhea, as defined by 
no  menses  for  greater  than  12  months.  All  women 
with gynecologic malignancy and some with breast 
cancer experienced surgically-induced menopause as 
a result of treatment (n=37). Of the 67 women who did 
not undergo surgically-induced menopause, 38 (56%) 
went on to experience amenorrhea.  
Table 1: Demographics and clinical characteristics of subjects. 
Disease  All  Breast   Gyn  General  BMT 
N (%)  104 (100)  38 (36)  26 (25)  20 (19)  20 (19) 
One year follow-up    53 (100)  21 (40)  14 (26)  9 (17)   9 (17) 
Age 
 <35  27 (26)  5 (13)  4 (15)  7 (35)  11 (55) 
 35-39  21 (20)  9 (24)  7 (27)  3 (15)  2 (10) 
 40-44  28 (27)  9 (24)  9 (35)  6 (30)  4 (20) 
 >44  28 (27)  15 (39)  6 (23)  4 (20)  3 (15) 
Marital Status   
 Single  41 (40)  13 (34)  13 (50)  9 (45)  6 (32) 
 Married  60 (58)  24 (63)  13 (50)  10 (50)  13 (68) 
 Divorced  2 (2.0)  1 (3.0)  0 (0.0)  1 (5.0)  0 (0.0) 
Median Time Since Diagnosis (yrs)  2.4  2.8  1.5  2.2  3.0 
Gender of Oncologist   
 Male  46 (47)  18 (51)  3 (12.5)  11 (61)  14 (70) 
 Female  50 (52)  17 (49)  21 (87.5)  7 (39)  5 (25) 
Treatment Receiveda   
 Surgery  73  36  25  12  0 
 Chemotherapy  80  29  14  17  20 
 Radiation   33  12  9  8  4 
 Hormone Therapy  26  26  0  0  0 
 Stem Cell Transplant  22  0  0  0  22 
Treatment-induced Amenorrhea  67 (64)  23 (60)  22 (84)  6 (30)  16 (80) 
a Individual subjects may have received more than one modality of cancer therapy.  Journal of Cancer 2012, 3 
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During  the  course  of  the  year  between  enroll-
ment and the 1 year follow-up survey, five patients 
died due to disease progression. Of the remaining 99 
women, 53 completed the follow-up questionnaire for 
a response rate of 54%. Of the patients who responded 
to the follow-up survey, 36% were under the age of 39 
and 64% were ages 40 or older; whereas in the original 
survey cohort the distribution of patient age was 46% 
under the age of 39 and 54% ages 40 or older. Most 
women  who  completed  the  follow-up  survey  were 
married (66%), similar to the percentage of married 
patients  in  the  original  survey  (58%);  however 
non-responders  to  the  follow-up  survey  were  less 
likely to be married (48%). There were no differences 
between the original and 1-year follow-up cohorts in 
terms  of  the  distribution  of  patients  by  dis-
ease-specific cancer care (Table 1). Sixty-six percent of 
women in the follow-up survey were amenorrheic as 
compared to 64% in the initial survey. In general, the 
only appreciable difference between the patient char-
acteristics of those who responded to the 1-year fol-
low-up survey and those who completed the original 
survey is the distribution of patient age. Compared 
with the 1-year follow-up responders, non-responders 
were  more  likely  to  be  younger  (less  than  40)  and 
single. 
Patient Satisfaction with quality-of-life discus-
sions during treatment planning 
Patient  satisfaction  was  assessed  during  treat-
ment planning in terms of the quality and length of 
physician-patient  discussions  about  fertility,  meno-
pause, and sexual health topics (Figure 1). Overall, a 
majority  of  women  were  satisfied  with  the  quality 
(68%) and length (66%) of discussions during treat-
ment planning (Figure 1). Disease-specific cancer care 
significantly affected satisfaction ratings in the quality 
and length of conversation. Satisfaction was highest 
for the quality and length of conversation among gy-
necologic  cancer  patients  and  lowest  among  BMT 
cancer patients. Patients were most likely to be dis-
satisfied with conversation quality and length in the 
breast cohort, (p=.012, p=.036 respectively). Gender of 
the oncologist, patient age, and initial interest in fer-
tility preservation did not significantly affect patient 
satisfaction ratings for either conversation quality or 
length. Initial satisfaction levels remained unchanged 
among  those  women  who  responded  to  the  1-year 
follow-up study (n=53). 
Time spent on reproductive and sexual health 
discussions 
Forty seven (62%) women spent 1-10 minutes in 
their initial discussion of treatment impact on fertility, 
menopause, and sexual health with their treating on-
cologist  while  only  29  (38%)  women  spent  >10 
minutes in such discussions. Disease-specific cancer 
care significantly affected the length of initial discus-
sions  (p=.001).  Discussions  lasting  more  than  10 
minutes occurred for 14 (61%) women in the gyneco-
logic clinic, 9 (33%) women in the breast clinic, 5 (45%) 
in the general oncology clinic, and only 1 (7%) in the 
BMT  clinic.  Although  38  (41%)  women  had  two  or 
more  follow-up  discussions  about  fertility,  meno-
pause, and sexual health, 25 (27%) women reported 
no additional discussions. Fertility and reproductive 
health discussions were physician-initiated 73% of the 
time,  whereas  19  (23%)  women  had  to  initiate  the 
conversation  on  their  own.  Gender  of  oncologist, 
disease-specific  cancer  care,  or  patient  age  did  not 
significantly  affect  the  number  of  follow-up  discus-
sions or the initiator of discussions. 
Fertility and sexual health resources 
Only 13 (14%) women were encouraged to speak 
to a fertility specialist about fertility preservation. Age 
significantly affected this result, with 9 (38%) women 
<35 years old and only 1 (2%) woman ≥40 years old 
receiving this recommendation (P=.001); gender of the 
oncologist or disease-specific cancer care did not af-
fect  the  chance  of  fertility  specialist  referral.  Addi-
tional  resources  on  reproductive  health  topics  were 
provided to 35 (37%) women by their treating oncol-
ogist. Women in the gynecologic cancer clinic were 
2-3 fold more likely than those in other clinics to re-
ceive  these  additional  resources  (p=.026).  Fifty-one 
(54%)  women  reported  searching  for  additional  re-
sources on their own.  
Patient attitudes about fertility preservation 
over time and their impact on cancer treat-
ment choice 
Nineteen (20%) women ranked fertility preser-
vation  as  important  at  the  time  of  diagnosis  and 
treatment planning. These women were more likely to 
be of a younger age and with no previous pregnan-
cies.  While  fertility  preservation  was  ranked  as  im-
portant  16%  of  women  40-44  years  old,  only  one 
woman over the age of 40 was referred to a fertility 
specialist. Even though none of the women >44 years 
old were interested in preserving their own fertility, 
12% of these women found it important to discuss the 
risk of treatment-induced infertility. In addition, the 
risk of infertility affected treatment choice in 12 (13%) 
subjects; factors significantly affecting this result were 
younger age, being unmarried, and having no prior  Journal of Cancer 2012, 3 
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successful pregnancies.  
 After treatment completion, interest in fertility 
preservation was unchanged in 70% of women who 
were initially interested in fertility preservation and 
did  not  undergo  surgically-induced  menopause. 
Marital status and disease-specific cancer care did not 
affect the importance assigned to fertility preservation 
over time. Concern about cancer recurrence did affect 
interest in future pregnancies in 29% of women.  
Patient attitudes about reproductive and 
sexual health discussions  
Thirty-two  (31%)  women  reported  that  it  was 
important to have a discussion about treatment im-
pact on fertility at the time of diagnosis (Figure 2a). 
Women were more interested, however, in discussing 
treatment  impact  on  menopause  status  (n=69,  68%; 
Figure 2b) and general sexual health (n=55, 55%; Fig-
ure 2c). In general, fewer women were interested in 
discussing  the  impact  of  treatment  on  fertility  or 
menopause  status  (33%,  68%  respectively)  than  the 
percentage of those who actually had such a discus-
sion with their oncologist (77%, 82% respectively). In 
contrast, more women (55%) were interested in dis-
cussing  treatment  impact  on  general  sexual  health 
than the percentage of those (40%) who actually had 
such a discussion with their oncologist. This discrep-
ancy was exacerbated by disease-specific cancer care 
cohorts. Only 22% of women in the gynecologic clinic 
reported  no  conversation  of  treatment  impact  on 
sexual  health,  whereas  80%  of  those  in  the  breast 
cancer clinic and 82% in the BMT clinic reported no 
such discussion (p<.001). There was also significantly 
higher incidence of discussions of treatment  impact 
on sexual health led by female oncologists (p=.02). 
 
 
Fig 1. Patient satisfaction with quality (A) and length (B) of physician-patient discussions on treatment impact on fertility and sexual health. 
A Satisfaction with Quality of Discussion.  Journal of Cancer 2012, 3 
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Fig 2. Patient interest and discussions that occurred regarding treatment impact on fertility (A), menopause status (B), and sexual health 
(C).  Journal of Cancer 2012, 3 
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Fig 3. Changes in sexual dysfunction over time. 
 
The importance of discussing treatment impact 
on  general  sexual  health  was  rated  significantly 
higher at 1-year follow-up. Thirty-two (62%) women 
in  the  follow-up  survey  had  initially  ranked  sexual 
health  discussions  as  important  compared  with  41 
(79%) one year later (p=.039). Age, marital status, and 
menopausal  status  did  not  affect  attitudes  toward 
reproductive  or  sexual  health  discussions.  Patient 
attitudes about discussing treatment impact on fertil-
ity or menopause remained unchanged. 
Treatment impact on sexual health over time 
Rates  of sexual dysfunction were  high and in-
creased over time, with 77% of women reporting se-
vere problems with at least one of the sexual health 
domains  (libido,  vaginal  dryness,  dyspareunia,  pa-
tient  satisfaction  and  partner  satisfaction)  at  1-year 
follow-up (Figure 3). Dyspareunia (p=.058) and part-
ner satisfaction (p=.013) specifically were significantly 
worse at 1-year follow-up. Only menopausal status, 
but not age or marital status, significantly influenced 
rates of sexual dysfunction. At 1-year follow-up, 19 
(83%) women experiencing severe sexual side effects 
were  amenorrheic,  whereas  only  4  (17%)  were  not 
amenorrheic  (p=.027).  The  rate  of  amenorrhea  was 
unchanged over time (64% at baseline versus 66% at 
follow-up), therefore the higher rates of sexual dys-
function  likely  represent  the  effect  of  prolonged 
amenorrhea rather than higher rates of it. 
Patient interest in alternative methods of fer-
tility after treatment  
After  cancer  treatment,  there  were  67  women 
who  had  not  experienced  surgically-induced  meno-
pause.  Of  these  women,  21%  reported  interest  in 
adoption, surrogacy, or other methods of fertility after 
treatment.  Younger  age  and  lack  of  previous  preg-
nancies,  but  not  disease-specific  cancer  care,  were 
significantly  associated  with  interest  in  adoption, 
surrogacy, and other methods of fertility.  
Discussion 
The  present  study  demonstrates  that  female 
cancer  survivors  are  generally  satisfied  with  physi-
cian-patient discussions of treatment impact on fertil-
ity, menopause status and sexual health as they nav-
igate through the cancer treatment process. Satisfac-
tion  rates  were  markedly  different  within  the  dis-
ease-specific  clinics,  with  highest  levels  achieved  in 
the  gynecologic  cancer  clinic.  These  results  are  not 
unexpected, given the proximity of the cancer to re-
productive  organs,  physician  familiarity  with  these 
topics, and the fact that more time was allocated to 
discuss these topics in clinic. However, one area of 
concern  raised  by  our  study  is  that  discussions  of 
treatment  impact  on  general  sexual  health  were  in-
frequent despite high demand for them. This is trou-
bling since the overwhelming majority of women ex-
perienced  severe  sexual  dysfunction,  especially  in 
those  who  also  experienced  treatment-induced 
amenorrhea. This finding is consistent with previous 
reports.7,8 Additionally, we found that disturbances in 
sexual function were  not  short-lived and  may have 
worsened  over  time.  Oncologists,  and  in  particular 
male oncologists, did not discuss the effect of treat-
ment  on  general  sexual  health  as  frequently  or  as 
in-depth  as  patients  had  hoped.  This  may  be  ex-
plained by a general lack of knowledge and training  Journal of Cancer 2012, 3 
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on this topic, in addition to its sensitive nature. Taken 
together, these data demonstrate that the  impact  of 
cancer treatment on general sexual health is particu-
larly  important  for  oncologists  to  address  during 
treatment planning and in survivorship follow-up. 
Studies involving female cancer survivors indi-
cate  that  many  women  desire  to  preserve  fertility 
during cancer treatment.3, 13-15 We found that the level 
of  interest  in  fertility  preservation  persisted 
post-therapy and had the power to influence cancer 
treatment choice when women had options, particu-
larly in the nulliparous cohort. Younger women were 
more likely to explore options such as surrogacy and 
adoption, further highlighting the necessity for access 
to  fertility  specialist  expertise.  The  paucity  of  addi-
tional  resources  and  fertility  specialist  referrals  to 
supplement  reproductive  health  discussions  and  to 
aid women in cancer treatment decisions is concern-
ing and reflects national trends. Our data demonstrate 
there is a significant desire for knowledge and coun-
seling of reproductive options at the time of cancer 
diagnosis regardless of age and initial interest in fer-
tility  preservation.  The  rates  by  which  discussions 
about  treatment  impact  on  fertility  and  referrals  to 
fertility specialists in women over the age of 40, were 
exceedingly low. This is despite the fact that at least 
16% of women in this age group expressed a desire for 
future pregnancy at the time of cancer diagnosis. This 
level of interest in future pregnancy among women 
over 40 years old is consistent with the increasingly 
common  delay  in  child  bearing,  with  9.5  per  1000 
births occurring in mothers age 40-44.16 We suspect 
that  barriers  to  fertility-related  care  include  inade-
quate physician awareness or support and insufficient 
institutional  funding  for  appropriate  fertility  and 
sexual health specialist care.  
This  study  has  several  strengths  including  its 
high participation rate of 90%. The authors, however, 
acknowledge its limitations. Given the median time 
since  cancer  diagnosis  of  2.4  years,  patients  could 
have been subject to recall bias when reporting the 
details  of  treatment  planning  discussions.  A  major 
strength of this study, however, is that it implemented 
a  1-year  follow-up  survey  with  duplicate  questions 
from the original. This was completed by 54% of par-
ticipants.  The  1-year  follow-up  results  demonstrate 
minimal variation compared with the original scores 
reported thus establishing consistency and validity of 
the data and limiting the possibility of recall bias.  
This study was designed to minimize the possi-
ble influence of its conduct on how physicians would 
typically approach these topics or the content or du-
ration of such reproductive and sexual health discus-
sions  with  their  patients.  Physicians  were  removed 
from the recruitment and consent process, and all but 
the four physician investigators were blinded to the 
content  of  the  study  questionnaire.  In  addition,  all 
eligible patients were either actively receiving cancer 
therapy  or  within  24  months  of  the  completion  of 
therapy at the time they completed the study ques-
tionnaire. Therefore the presence of the study inves-
tigators in the clinic could not change physician atti-
tudes or approach to these discussions with the en-
rolling  patients  as  their  treatment  planning  and  re-
productive  health  conversations  had  already  oc-
curred.  
Study participants in this single-institution study 
conducted  at  a  large, academic  medical  center  may 
not  fully  represent  patient  expectations,  values  or 
demographics in other geographic or more commu-
nity-based locations. In addition, these women were 
recruited from 3 separate subspecialty oncology clin-
ics as well as the general hematology and oncology 
clinic, and it is unknown whether subspecialty care 
and providers impact study results or if our conclu-
sions would be fully applicable to a unified oncology 
practice staffed by general oncologists. However, this 
study included over 100 young women with a wide 
spectrum  of  malignant  pathology.  The  needs,  con-
cerns, and opinions of these women that were eluci-
dated from this study may be utilized to address and 
appropriately  counsel  an  extensive  population  of 
young women facing any type of new cancer diagno-
sis.  
 In  conclusion,  one-third  of  pre-menopausal 
women with cancer are dissatisfied with the quality 
and length of oncologist discussions about the impact 
of cancer treatment on reproductive health. There is 
substantial room for improvement in communication 
and counseling of sexual health concerns, as well as 
the ability to provide resources and information for 
those  women  who  demonstrate  interest  in  fertility 
preservation. Further studies will be necessary to fo-
cus on the barriers to the oncologist’s ability to pro-
vide such discussions and resources and for the de-
velopment of interventions to overcome such barriers. 
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